Clinical Trial Update: Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. [Phase 3]

View source ↗

Summary

A Phase 3 trial of carfilzomib, daratumumab, and dexamethasone in patients with relapsed and/or refractory multiple myeloma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)
• Decadron (Dexamethasone)
• Kyprolis (carfilzomib)

Snippet

Sponsor: Amgen | Conditions: Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2020-09-11